398 related articles for article (PubMed ID: 16359315)
21. Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein.
Courtney HS; Hasty DL; Dale JB
Mol Microbiol; 2006 Feb; 59(3):936-47. PubMed ID: 16420362
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic variability of X-protein expression by mastitis-causing Streptococcus agalactiae of serotype NT/X and opsonic activities of specific antibodies.
Rainard P; Sarradin P; Poutrel B
Microb Pathog; 1994 May; 16(5):359-72. PubMed ID: 7815919
[TBL] [Abstract][Full Text] [Related]
23. Streptococcal defenses against host immune attack: the M protein-fibrinogen interaction.
Whitnack E; Dale JB; Beachey EH
Trans Assoc Am Physicians; 1983; 96():197-202. PubMed ID: 6208666
[No Abstract] [Full Text] [Related]
24. Sequence variability is correlated with weak immunogenicity in Streptococcus pyogenes M protein.
Lannergård J; Kristensen BM; Gustafsson MC; Persson JJ; Norrby-Teglund A; Stålhammar-Carlemalm M; Lindahl G
Microbiologyopen; 2015 Oct; 4(5):774-89. PubMed ID: 26175306
[TBL] [Abstract][Full Text] [Related]
25. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
Shaila MS; Nayak R; Prakash SS; Georgousakis M; Brandt E; McMillan DJ; Batzloff MR; Pruksakorn S; Good MF; Sriprakash KS
Vaccine; 2007 May; 25(18):3567-73. PubMed ID: 17293014
[TBL] [Abstract][Full Text] [Related]
26. Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence.
Gustafsson MC; Lannergård J; Nilsson OR; Kristensen BM; Olsen JE; Harris CL; Ufret-Vincenty RL; Stålhammar-Carlemalm M; Lindahl G
PLoS Pathog; 2013; 9(4):e1003323. PubMed ID: 23637608
[TBL] [Abstract][Full Text] [Related]
27. Functional dissection of Streptococcus pyogenes M5 protein: the hypervariable region is essential for virulence.
Waldemarsson J; Stålhammar-Carlemalm M; Sandin C; Castellino FJ; Lindahl G
PLoS One; 2009 Oct; 4(10):e7279. PubMed ID: 19794915
[TBL] [Abstract][Full Text] [Related]
28. Streptococcal M protein: structural studies of the hypervariable region, free and bound to human C4BP.
André I; Persson J; Blom AM; Nilsson H; Drakenberg T; Lindahl G; Linse S
Biochemistry; 2006 Apr; 45(14):4559-68. PubMed ID: 16584191
[TBL] [Abstract][Full Text] [Related]
29. Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein.
Kraus W; Haanes-Fritz E; Cleary PP; Seyer JM; Dale JB; Beachey EH
J Immunol; 1987 Nov; 139(9):3084-90. PubMed ID: 2444650
[TBL] [Abstract][Full Text] [Related]
30. Synthetic peptide fragments of streptococcal M proteins.
Seyer JM; Dale JB; Beachey EH
Dev Biol Stand; 1986; 63():101-8. PubMed ID: 2427375
[TBL] [Abstract][Full Text] [Related]
31. Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium.
Baird RW; Bronze MS; Kraus W; Hill HR; Veasey LG; Dale JB
J Immunol; 1991 May; 146(9):3132-7. PubMed ID: 2016540
[TBL] [Abstract][Full Text] [Related]
32. A highly variable region in members of the streptococcal M protein family binds the human complement regulator C4BP.
Johnsson E; Thern A; Dahlbäck B; Hedén LO; Wikström M; Lindahl G
J Immunol; 1996 Oct; 157(7):3021-9. PubMed ID: 8816411
[TBL] [Abstract][Full Text] [Related]
33. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
34. Affects of N-terminal variation in the SeM protein of Streptococcus equi on antibody and fibrinogen binding.
Timoney JF; DeNegri R; Sheoran A; Forster N
Vaccine; 2010 Feb; 28(6):1522-7. PubMed ID: 20005857
[TBL] [Abstract][Full Text] [Related]
35. Mapping the immunodeterminants of the complete streptococcal M6 protein molecule. Identification of an immunodominant region.
Fischetti VA; Windels M
J Immunol; 1988 Nov; 141(10):3592-9. PubMed ID: 2460540
[TBL] [Abstract][Full Text] [Related]
36. Group A streptococcus expresses a trio of surface proteins containing protective epitopes.
Niedermeyer SE; Penfound TA; Hohn C; Li Y; Homayouni R; Zhao J; Dale JB
Clin Vaccine Immunol; 2014 Oct; 21(10):1421-5. PubMed ID: 25080552
[TBL] [Abstract][Full Text] [Related]
37. Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis.
Jacks-Weis J; Kim Y; Cleary PP
J Immunol; 1982 Apr; 128(4):1897-902. PubMed ID: 7037956
[TBL] [Abstract][Full Text] [Related]
38. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
39. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
40. Application of immunoproteomics to analysis of post-translational processing of the antiphagocytic M protein of Streptococcus.
Romer TG; Boyle MD
Proteomics; 2003 Jan; 3(1):29-35. PubMed ID: 12548631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
